Long-Term Outcome of Sirolimus Rescue in Kidney-Pancreas Transplantation

Sirolimus (SRL) rescue in kidney-pancreas transplantation has not been well described. We reviewed 112 KPTxs performed at our institution between December 3, 1995 and June 27, 2002. All patients received antibody induction, tacrolimus (TAC), mycophenolate mofetil (MMF), and steroids. In 35 patients, SRL was substituted for MMF for the following reasons: acute rejection (AR) of kidney or pancreas despite adequate TAC levels, MMF intolerance, increasing creatinine levels, and TAC-induced hyperglycemia. Three-year kidney and pancreas graft survivals were 97% and 90%, respectively. Of 10 patients who were switched to SRL because of AR, one kidney failed because of antibody-resistant AR, and one kidney developed borderline AR; the other eight patients remain AR-free. AR developed in seven other patients despite therapeutic SRL levels; six had TAC levels less than 4.5 ng/mL. The mean creatinine levels overall and for the group with increasing creatinine remained stable. All patients who were switched to SRL for TAC-induced hyperglycemia or MMF intolerance improved. Kidney-pancreas transplant recipients can be safely switched to SRL with excellent graft and patient survival.

[1]  M. Castagneto,et al.  Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients. , 2003, Transplantation proceedings.

[2]  C. V. van Buren,et al.  Thymoglobulin, sirolimus, and reduced-dose cyclosporine provides excellent rejection prophylaxis for pancreas transplantation , 2003, Transplantation.

[3]  K. Baboolal.  A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients1,2 , 2003, Transplantation.

[4]  F. Schena,et al.  Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination1, 2 , 2002, Transplantation.

[5]  M. Abecassis,et al.  A PROSPECTIVE STUDY OF RAPID CORTICOSTEROID ELIMINATION IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION: Comparison of Two Maintenance Immunosuppression Protocols: Tacrolimus/Mycophenolate Mofetil Versus Tacrolimus/Sirolimus1 , 2002, Transplantation.

[6]  R. Oberbauer,et al.  SIROLIMUS ALLOWS EARLY CYCLOSPORINE WITHDRAWAL IN RENAL TRANSPLANTATION RESULTING IN IMPROVED RENAL FUNCTION AND LOWER BLOOD PRESSURE1,2,10 , 2001, Transplantation.

[7]  D. Sutherland,et al.  Analyses of pancreas transplant outcomes for United States cases reported to the United Network for Organ Sharing (UNOS) and non-US cases reported to the International Pancreas Transplant Registry (IPTR). , 1999, Clinical transplants.

[8]  R. Stratta.  Immunosuppression in pancreas transplantation: progress, problems and perspective. , 1998, Transplant immunology.

[9]  D. Dunn,et al.  Simultaneous pancreas-kidney transplant versus kidney transplant alone in diabetic patients. , 1992, Kidney international.